CTOs on the Move


 
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.altpep.com
  • 100 NE Northlake Way Suite 300
    Seattle, WA USA 98105
  • Phone: N/A

Executives

Name Title Contact Details

Funding

AltPep raised $23.1M on 01/12/2021

Similar Companies

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gameto

Gameto is a biotechnology company that uses cell engineering to develop novel therapeutics for the diseases of the female reproductive system.

Morphic Therapeutic

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.

Silk Technologies

SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company`s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.

HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.